Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials

A Moore; L Green; S Bruce; N Sadick; E Tschen; P Werschler; S Dhawan; D Forsha; M Gold; S Guenthner; S Kempers; L Kircik; J Parish; M Rendon; P Rich; L Stein-Gold; S Tyring; R Weiss; A Nasir; C Schmitz; T Boodhoo; A Kaoukhov; D Berk; F Cook-Bolden; Ayman Grada

A Moore
L Green
S Bruce
N Sadick
E Tschen
P Werschler
S Dhawan
D Forsha
M Gold
S Guenthner
S Kempers
L Kircik
J Parish
M Rendon
P Rich
L Stein-Gold
S Tyring
R Weiss
A Nasir
C Schmitz
T Boodhoo
A Kaoukhov
D Berk
F Cook-Bolden
Ayman Grada

Keywords

Acne Vulgaris, Sarecycline

Abstract

Abstract not available.

References

1. A, Green LJ, Bruce S, et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. Journal of drugs in dermatology: JDD. 2018 Sep;17(9):987-96.

Poster PDF

Published

Jan 28, 2020

How to Cite

Moore, A., Green, L., Bruce, S., Sadick, N., Tschen, E., Werschler, P., Dhawan, S., Forsha, D., Gold, M., Guenthner, S., Kempers, S., Kircik, L., Parish, J., Rendon, M., Rich, P., Stein-Gold, L., Tyring, S., Weiss, R., Nasir, A., Schmitz, C., Boodhoo, T., Kaoukhov, A., Berk, D., Cook-Bolden, F., & Grada, A. (2020). Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials. SKIN The Journal of Cutaneous Medicine, 4(1), S14. Retrieved from https://jofskin.org/33014/index.php/skin/article/view/811

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Acne & Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee, Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
N Bhatia, W Werschler, H Baldwin, J Sugarman, L Stein Gold, L Green, E Lain, Long-Term Efficacy and Safety of Benzoyl Peroxide Cream, 5%, Prepared with Microencapsulation in Papulopustular Rosacea: Results from an Extension of Two Phase 3, Vehicle-Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl, Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl, Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola, Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Emmy Graber, Hilary Baldwin, Julie C Harper, Linda Stein Gold, Ayman Grada, Andrew F Alexis, Adelaide A Hebert, Richard G Fried, Evan A Rieder, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Leon Kircik, Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)